All News
Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read Article
NSAIDs in Pregnancy (3.3.2023)
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
Read Article
The Late Edition (2.24.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 @RheumNow https://t.co/S3NQ4mWgjt
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
SURPASS: SEC vs ADA for axSpA
Outcome: %pts with no radiographic progression
Not benefit- Secukinumab not better than adalimumab
Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well!
@RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Eric Dein ericdeinmd ( View Tweet)
First Head-to-Head bDMARD study in axSpA to assess radiographic progression
- secukinumab vs. adalimumab biosimilar
- 66% of either arm prevented radiographic progression
- no difference between two arms but good news is radiographic progression is low!
@RheumNow #RNL2023 https://t.co/xq8GhN7kzr
Robert B Chao, MD doctorRBC ( View Tweet)
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met.
However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC
Dr. Rachel Tate uptoTate ( View Tweet)
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different? niche category for IL-17A and F use?
@RheumNow #RNL2023 https://t.co/dWkakahHAi
Robert B Chao, MD doctorRBC ( View Tweet)
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/ySk4hU5lMY
Eric Dein ericdeinmd ( View Tweet)
To differentiate mechanical from inflammatory lesion:
1-Site matters
2-Structural changes matter
Denis Poddubnyy #RNL2023 @RheumNow https://t.co/iQ1gHPnkqO
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Stanley Cohen on JAKinibs:
Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions
@RheumNow #RNL2023 https://t.co/3ZZHr0akrR
Robert B Chao, MD doctorRBC ( View Tweet)
Swedish registry of Axial SpA pregnancies, 1580 births (matched 1:10), saw improved Preg outcomes & incr biologic use. SpA pts had signif. incr in preterm (RR 1·43), preeclampsia (1·44), C-Sect (1·59), infant SIE (1·29) - Each decreased by annually 0.5% https://t.co/EAUwxNsgzH https://t.co/tmNi3dQtMK
Links:
Dr. John Cush RheumNow ( View Tweet)
32 men w/ B27+ #AS (Rx NSAIDs, BASDAI ~5.3) underwent exercise training (10d, 60min) w/ or w/o Pre-Rx w/ whole-body cryotherapy (WBC). WBC had significant drops in hsCRP, sP-Selectin, sVCAM-1, neopterin & signif decreases in BASDAI, BASFI, pain intensity https://t.co/8bmjTS4VOk https://t.co/ajrD8Z7C8v
Links:
Dr. John Cush RheumNow ( View Tweet)
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://t.co/KTYn1kv3qO https://t.co/eWbvMSBLxm
Links:
Dr. John Cush RheumNow ( View Tweet)
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients
Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the ACR.
https://t.co/514mIylgzj https://t.co/9Zq9pGcujV
Links:
Dr. John Cush RheumNow ( View Tweet)
Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Disease - IBD Overlap
Nearly one in 10 patients with IBD also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested.
https://t.co/s3u9q8Sw9Y https://t.co/RjFyEcm6FA
Links:
Dr. John Cush RheumNow ( View Tweet)
AS, but not PsA, has Increased Mortality Risk
A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality.
https://t.co/bi3q7LW4S6 https://t.co/DUc9sB4MI0
Links:
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx
Links:
Dr. John Cush RheumNow ( View Tweet)
